Chemomab Therapeutics CMMB
NASDAQ CMMB
$1.17 0.00 (-0.42%)
As of: Oct 21, 2026 · 3:30 PM EDT

Chemomab Therapeutics (CMMB) Restructuring Costs (2020)

Updated

Chemomab Therapeutics (CMMB) reported Restructuring Costs of $749,000 for FY2020, down 77.6% from $3.35 million in FY2019.

Analysis

Chemomab Therapeutics (CMMB) Restructuring Costs (2020) Analysis & Trends

  • According to Business Quant data, Restructuring Costs came in at $3.35 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Chemomab Therapeutics 7.49 Mn -27.66 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 79,000.00
Mar 31, 2020 670,000.00
API Access

Chemomab Therapeutics Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=CMMB&period=max&api_key=YOUR_API_KEY